Cargando…
Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months
INTRODUCTION: Given the pathophysiology of coronavirus disease 19 (COVID-19), persistent pulmonary abnormalities are likely. METHODS: We conducted a prospective cohort study in severe COVID-19 patients who had oxygen saturation < 94% and were primarily admitted to hospital. We aimed to describe p...
Autores principales: | Noel-Savina, E., Viatgé, T., Faviez, G., Lepage, B., Mhanna, L.t, Pontier, S., Dupuis, M., Collot, S., Thomas, P., Idoate Lacasia, J., Crognier, L., Bouharaoua, S., Silva Sifontes, S., Mazieres, J., Prévot, G., Didier, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SPLF and Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080504/ https://www.ncbi.nlm.nih.gov/pubmed/34242974 http://dx.doi.org/10.1016/j.resmer.2021.100822 |
Ejemplares similares
-
Syndrome de Parsonage-Turner compliquant une infection sévère à SARS-CoV-2
por: Viatgé, T., et al.
Publicado: (2021) -
USIR : unité pivot des détresses respiratoires : une année de pandémie à SARS-CoV-2
por: Foulquier, S., et al.
Publicado: (2022) -
Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019) -
Confocal laser endomicroscopy to guide sampling of a pure ground-glass opacity
por: Viatgé, Thibault, et al.
Publicado: (2021) -
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
por: Mhanna, Laurent, et al.
Publicado: (2019)